Immunotoxin fusion proteins and means for expression thereof

US7696338B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Department of Health and Human Services · US
• Novartis AG · CH

Inventors

• David M. Neville, Jr. · Bethesda, US
• Jerry T. Thompson · Goose Creek, US
• Huaizhong Hu · Madison, US
• Jung-Hee Woo · Temple, US
• Shenglin Ma · Indianapolis, US
• Jonathan Mark Hexham · Dallas, US
• Mary Ellen Digan · Winchester, US

Key dates

• Filing date: May 18, 2001
• Grant date: Apr 13, 2010
• Expiry date: Nov 11, 2025

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention described and shown in the specification and drawings provides novel recombinant DT-based immunotoxins, and, more specifically anti-T cell immunotoxin fusion proteins. Also provided are immunotoxins that can be expressed in bacterial, yeast, or mammalian cells. The invention also provides means for expression of the immunotoxin fusion protein.